InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,465.27
(
-0.14%
)
US TECH 100
19,223.60
(
-0.18%
)
Dow Jones
39,170.91
(
0.09%
)
Brent Oil
84.39
(
-0.73%
)
Bitcoin
63,866.30
(
-1.47%
)
Post# of 120
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

dcaf7

Send PM Follow Ignore
Followers 3
Posts 292
Boards Moderated 0
Alias Born 12/21/2022

dcaf7

Re: G. Angue post# 108

Wednesday, 05/15/2024 3:13:11 PM

Wednesday, May 15, 2024 3:13:11 PM

Post# of 120
I think, 1st line patient population with non-classical mutations is ~20,000. Not sure about cost. Osimertinib is ~$18,000/month.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent BDTX News
More BDTX News
InvestorsHub NewsWire

Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM

ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM

North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM

VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM

Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM

Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM

Start posting your company's news
Only $200 per official company press release!